On the stock market since 1982, it operates in the world of health and science. It has 37,000 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The gap is $13.8B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 15% off the top. A pullback, not a collapse.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
The average analyst price target is $41.00 — 32% above today’s price.
It pays out $0.85 per share each year — regular cash for whoever holds the stock.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, TEVA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TEVA is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.